Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

Reddy KR, Bourliere M, Sulkowski MS, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Omata M, Zeuzem S, Feld JJ, Lawitz EJ, Marcellin P, Welzel TM, et al. Hepatology. 2015;62(1):79-86.

Publication Type:

Journal Article

Authors:

K R Reddy; Bourliere, M.; M S Sulkowski; et, al

Source:

Hepatology, Volume 62, Issue 1, p.79-86 (2015)

Keywords:

analysis, Antiviral Agents, Asthenia, Baltimore, Boston, Canada, Cities, clinical trial, Clinical Trials, Fatigue, France, Genotype, genotype 1, Germany, HCV, Headache, Health, hepatitis, Hepatitis C, hepatitis C virus, immunology, Infection, Israel, Italy, Japan, Liver, Medicine, New Zealand, Ontario, Paris, Patients, Philadelphia, protease inhibitor, Research, Ribavirin, Safety, sofosbuvir, SVR, Texas, therapy, treatment, treatment-naive, Universities

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25846144

Export Citation:

RIS Format

Top